3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
402
Triple Negative Breast Neoplasms
64
Neoplasm Metastasis
50
Neoplasms
19
Breast Neoplasms, Male
14
Colorectal Neoplasms
13
Brain Neoplasms
13
Stomach Neoplasms
11
Pancreatic Neoplasms
11
Colonic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Inflammatory Breast Neoplasms
6
HER2-positive Breast Cancer
6
Squamous Cell Carcinoma of Head and Neck
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Advanced Breast Cancer
5
Rectal Neoplasms
4
HER2 Positive Metastatic Breast Cancer
4
Breast Cancer Metastatic
4
Sarcoma
3
Prostatic Neoplasms
3
Meningeal Neoplasms
3
Lymphoma, Non-Hodgkin
3
Gallbladder Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Small Cell Lung Carcinoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Unknown Primary
2
Interventions
pembrolizumab
2
tocilizumab
1
poly ICLC
1
flt3 ligand protein
1
cemiplimab
1
SUB1 protein, human
1
Radiotherapy
1
Radiation
1
Interleukin-2
1
Capecitabine
1
Antineoplastic Protocols
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Basal Cell
×
Capecitabine
×
Breast
×
Clear all
NCT03775525
2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1
Unknown
127 enrolled